VC fund dedicated to psychedelic meds launches in UKIn the last few years, biopharma companies focusing on psychedelic medicines have been springing up like mushrooms – Share XVC fund dedicated to psychedelic meds launches in UKhttps://pharmaphorum.com/news/vc-fund-dedicated-to-psychedelic-meds-launches-in-uk/
Purdue to pay $8.3bn after admitting criminal charges in opioid caseAfter years of legal wrangling, Purdue Pharma has agreed a deal to resolve litigation about its role in Share XPurdue to pay $8.3bn after admitting criminal charges in opioid casehttps://pharmaphorum.com/news/purdue-to-pay-8-3bn-after-admitting-criminal-charges-in-opioid-case/
After final $600M opioid settlement, Indivior looks to the futureUK drugmaker Indivior looks finally to have put years of uncertainty over its exposure to opioid litigation in Share XAfter final $600M opioid settlement, Indivior looks to the futurehttps://pharmaphorum.com/news/after-final-600m-opioid-settlement-indivior-looks-to-the-future/
Orexo eyes launch of digital therapy for heavy drinkers this yearOrexo has submitted its Vorvida digital therapy for the treatment of heavy drinking for approval by the FDA, Share XOrexo eyes launch of digital therapy for heavy drinkers this yearhttps://pharmaphorum.com/news/orexo-eyes-launch-of-digital-therapy-for-heavy-drinkers-this-year/
Addiction firm Orexo licenses app for alcohol use disorderSwedish drugmaker Orexo, best known for its opioid addiction therapies, has licensed rights to a digital therapy that Share XAddiction firm Orexo licenses app for alcohol use disorderhttps://pharmaphorum.com/news/addiction-firm-orexo-licenses-app-for-alcohol-use-disorder/
England is risking its own opioid epidemic, says PHEHundreds of thousands of people in England are at risk of dependency on prescription medicines like opioid painkillers, Share XEngland is risking its own opioid epidemic, says PHEhttps://pharmaphorum.com/news/england-is-risking-its-own-opioid-epidemic-says-phe/
FDA to reconsider Braeburn’s opioid addiction drug after court rulingA US district court has ruled that the FDA must reconsider its decision to reject a long-lasting opioid Share XFDA to reconsider Braeburn’s opioid addiction drug after court rulinghttps://pharmaphorum.com/news/fda-to-reconsider-braeburns-opioid-addiction-drug-after-court-ruling/
Beckley Canopy Therapeutics raises £7.4m for cannabis R&DOxford-based biopharma Beckley Canopy Therapeutics has raised £7.4 million to develop a range of cannabis-based products for the Share XBeckley Canopy Therapeutics raises £7.4m for cannabis R&Dhttps://pharmaphorum.com/news/beckley-canopy-therapeutics-raises-7-4m-for-cannabis-rd/
Trump signs legislation to tackle opiate addictionPresident Donald Trump has signed new legislation into law that he hopes will “end the scourge” of addiction Share XTrump signs legislation to tackle opiate addictionhttps://pharmaphorum.com/news/trump-signs-legislation-to-tackle-opiate-addiction/
